India Thalassemia Market Research Report

List of Tables

India Thalassemia Market Research Report Forecast to 2032

Market Overview

India Thalassemia Market is anticipated to register a CAGR of 5.19% during the review period. Thalassemia is a genetic blood condition in which the human body produces an abnormal kind of haemoglobin. It causes a huge number of blood cells to be destroyed, resulting in anaemia. Thalassemia is a genetic condition caused by the deletion or modification of a specific gene segment. If only one parent carries the gene, the child may get thalassemia mild. If both parents are chronic carriers, the child may acquire a severe version of the disease.

The growing government initiatives and support to raise awareness for thalassemia and the increased prevalence of thalassemia in India are major factors driving the growth of the Indian thalassemia market. However, the side effects associated with thalassemia drug treatment are expected to hamper the growth of the Indian market. Nevertheless, the advancements in prenatal and newborn screening technologies are anticipated to create lucrative opportunities for the players operating in the Indian market.

Market Segmentation

Based on type, the India thalassemia market has been bifurcated into alpha-thalassemia and beta-thalassemia.

On the basis of treatment & diagnosis, the India thalassemia market is segmented into treatment & diagnosis. diagnosis further segment into instruments and reagents.

Major Players

The key companies operating in India Thalassemia market are Cadila Pharmaceuticals, Centruion Remedies Private Limited, Agios Pharmaceuticals, Inc., Cipla Inc, Healing Pharma India Pvt. Ltd. (HPIPL), Rewine Pharmaceutical, Trexgen Pharmaceuticals Pvt. Ltd., Novartis AG, Bristol-Myers Squibb, and Sun Pharmaceutical Industries Ltd.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research DATA FLOW:
- 3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
- 3.7.1 Data forecasting Technique
3.8 DATA MODELLING
- 3.8.1 microeconomic factor analysis:
- 3.8.2 Data MODELLING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 Growing government initiatives and support to raise awareness for thalassemia
- 4.2.2 Increased prevalence of Thalassemia in india
4.3 RESTRAINTS
- 4.3.1 side effects associated with thalassemia drug treatment
4.4 OPPORTUNITY
- 4.4.1 Launch of services with Advancements in prenatal and newborn screening technologies

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 Threat of New Entrants
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 Threat of Substitutes
- 5.1.4 Bargaining Power of Buyers
- 5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE INDIA THALASSEMIA MARKET

6 INDIA THALASSEMIA MARKET, BY TYPE

6.1 INTRODUCTION

7 INDIA THALASSEMIA MARKET, BY TREATMENT & DIAGNOSIS

7.1 INTRODUCTION
7.2 TREATMENT
7.3 DIAGNOSIS

8 COMPETITIVE LANDSCAPE

8.1 INTRODUCTION
8.2 MARKET SHARE ANALYSIS,47
8.3 COMPETITOR DASHBOARD
8.4 PUBLIC PLAYERS STOCK SUMMARY
8.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
8.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 8.6.1 Product Launch

9 COMPANY PROFILES

9.1 CADILA PHARMACEUTICALS
- 9.1.1 COMPANY OVERVIEW
- 9.1.2 FINANCIAL OVERVIEW
- 9.1.3 productS OFFERED
- 9.1.4 KEY DEVELOPMENTS
- 9.1.5 SWOT ANALYSIS
- 9.1.6 KEY STRATEGIES
9.2 AGIOS PHARMACEUTICALS, INC
- 9.2.1 COMPANY OVERVIEW
- 9.2.2 FINANCIAL OVERVIEW
- 9.2.3 products OFFERED
- 9.2.4 KEY DEVELOPMENTS
- 9.2.5 KEY STRATEGIES
9.3 CIPLA INC
- 9.3.1 COMPANY OVERVIEW
- 9.3.2 FINANCIAL OVERVIEW
- 9.3.3 productS OFFERED
- 9.3.4 KEY DEVELOPMENTS
- 9.3.5 KEY STRATEGIES
9.4 NOVARTIS AG
- 9.4.1 COMPANY OVERVIEW
- 9.4.2 FINANCIAL OVERVIEW
- 9.4.3 PRODUCTS OFFERED
- 9.4.4 KEY DEVELOPMENTS
- 9.4.5 SWOT ANALYSIS
- 9.4.6 KEY STRATEGIES
9.5 CENTURION REMEDIES PRIVATE LIMITED
- 9.5.1 COMPANY OVERVIEW
- 9.5.2 FINANCIAL OVERVIEW
- 9.5.3 Products OFFERed
- 9.5.4 KEY DEVELOPMENTS
- 9.5.5 KEY STRATEGIES
9.6 HEALING PHARMA INDIA PVT. LTD.
- 9.6.1 COMPANY OVERVIEW
- 9.6.2 FINANCIAL OVERVIEW
- 9.6.3 Products OFFERed
- 9.6.4 KEY DEVELOPMENTS
- 9.6.5 KEY STRATEGIES
9.7 REWINE PHARMACEUTICAL
- 9.7.1 COMPANY OVERVIEW
- 9.7.2 FINANCIAL OVERVIEW
- 9.7.3 Products OFFERed
- 9.7.4 KEY DEVELOPMENTS
- 9.7.5 KEY STRATEGIES
9.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 9.8.1 COMPANY OVERVIEW
- 9.8.2 FINANCIAL OVERVIEW
- 9.8.3 PRODUCTS OFFERED
- 9.8.4 KEY DEVELOPMENTS
- 9.8.5 SWOT ANALYSIS
- 9.8.6 KEY STRATEGIES
9.9 BRISTOL-MYERS SQUIBB COMPANY
- 9.9.1 COMPANY OVERVIEW
- 9.9.2 FINANCIAL OVERVIEW
- 9.9.3 PRODUCTS OFFERED
- 9.9.4 KEY DEVELOPMENTS
- 9.9.5 SWOT ANALYSIS
- 9.9.6 KEY STRATEGIES
9.10 TREXGEN PHARMACEUTICALS PVT. LTD.
- 9.10.1 COMPANY OVERVIEW
- 9.10.2 FINANCIAL OVERVIEW
- 9.10.3 PRODUCTS OFFERED
- 9.10.4 KEY DEVELOPMENTS
- 9.10.5 KEY STRATEGIES

10 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELLING FOR MARKET SHARE ASSESSMENT
TABLE 2 INDIA THALASSEMIA MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 3 INDIA THALASSEMIA MARKET, BY TREATMENT & DIAGNOSIS, 2019-2032 (USD MILLION)
TABLE 4 INDIA THALASSEMIA MARKET, FOR TREATMENT, BY TYPE 2019-2032 (USD MILLION )
TABLE 5 INDIA THALASSEMIA MARKET, FOR DIAGNOSIS, BY TYPE 2019-2032 (USD MILLION)
TABLE 6 INDIA THALASSEMIA MARKET, FOR DIAGNOSIS, BY TYPE 2019-2032 (VOLUME UNITS)
TABLE 7 INDIA THALASSEMIA MARKET, FOR INSTRUMENTS, BY TYPE 2019-2032 (VOLUME UNITS)
TABLE 8 INDIA THALASSEMIA MARKET, FOR REAGENTS, BY TYPE 2019-2032 (VOLUME UNITS)
TABLE 9 PUBLIC PLAYERS STOCK SUMMARY
TABLE 10 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 11 PRODUCT LAUNCH
TABLE 12 CADILA PHARMACEUTICALS: PRODUCT OFFERED
TABLE 13 AGIOS PHARMACEUTICALS, INC: PRODUCT OFFERED
TABLE 14 AGIOS PHARMACEUTICALS, INC: KEY DEVELOPMENTS
TABLE 15 CIPLA INC: PRODUCT OFFERED
TABLE 16 NOVARTIS AG: PRODUCTS OFFERED
TABLE 17 CENTURION REMEDIES PRIVATE LIMITED: PRODUCTS OFFERED
TABLE 18 HEALING PHARMA INDIA PVT. LTD.: PRODUCTS OFFERED
TABLE 19 REWINE PHARMACEUTICAL: PRODUCTS OFFERED
TABLE 20 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW
TABLE 21 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 22 BRISTOL-MYERS SQUIBB COMPANY: PRODCUTS OFFERED
TABLE 23 TREXGEN PHARMACEUTICALS PVT. LTD.: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1INDIA THALASSEMIA MARKET: STRUCTURE
FIGURE 2INDIA THALASSEMIA MARKET REPORT: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5PORTER'S FIVE FORCES ANALYSIS: INDIA THALASSEMIA MARKET
FIGURE 6INDIA THALASSEMIA MARKET; TYPE SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 7INDIA THALASSEMIA MARKET, BY TYPE, 2022 & 2032 (USD MILLION)
FIGURE 8INDIA THALASSEMIA MARKET SHARE (%), BY TYPE, 2022
FIGURE 9INDIA THALASSEMIA MARKET; TREATMENT SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 10INDIA THALASSEMIA MARKET, BY TREATMENT, 2022 & 2032 (USD MILLION)
FIGURE 11INDIA THALASSEMIA MARKET SHARE (%), BY TREATMENT & DIAGNOSIS, 2022
FIGURE 12INDIA THALASSEMIA MARKET PLAYERS: COMPETITIVE ANALSIS, 2022
FIGURE 13COMPETITOR DASHBOARD: INDIA THALASSEMIA MARKET
FIGURE 14CADILA PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15CADILA PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 16AGIOS PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17CIPLA INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19NOVARTIS AG: SWOT ANALYSIS
FIGURE 20SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 21BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW
FIGURE 22BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS

India Thalassemia Market Research Report - Forecast to 2032

Description

Table of Contents